Patents by Inventor Shyamsundar Subramanian
Shyamsundar Subramanian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240131069Abstract: Provided herein are tumor-infiltrating lymphocytes (TILs) engineered to express a membrane-bound interleukin 15 (mbIL15). The mbIL15 TILs can be expanded in vitro using a rapid expansion protocol without the use of exogenous interleukin 2 (IL2) and can be used in adoptive cell therapy without concomitant use of an exogenous cytokine such as IL2. The TIL can be further engineered such that the mbIL15 is operably linked to one or more drug responsive domains (DRDs), polypeptides that can regulate the abundance and/or activity of the IL15 upon binding of the DRD with a ligand. Also provided herein are components for making the modified TILs and methods for making and using the modified TILs.Type: ApplicationFiled: November 2, 2023Publication date: April 25, 2024Applicant: OBSIDIAN THERAPEUTICS, INC.Inventors: Mithun Khattar, Shyamsundar Subramanian, Rachel Burga, Michelle Lynn Ols, Jan ter Meulen, Kyle Pedro, Jeremy Hatem Tchaicha
-
Publication number: 20240108722Abstract: Provided herein are tumor-infiltrating lymphocytes (TILs) engineered to express a membrane-bound interleukin 15 (mbIL15). The mbIL15 TILs can be expanded in vitro using arapid expansion protocol without the use of exogenous interleukin 2 (IL2) and can be used in adoptive cell therapy without concomitant use of an exogenous cytokine such as IL2. The TIL can be further engineered such that the mbIL15 is operably linked to one or more drug responsive domains (DRDs), polypeptides that can regulate the abundance and/or activity of the IL15 upon binding of the DRD with a ligand. Also provided herein are components for making the modified TILs and methods for making and using the modified TILs.Type: ApplicationFiled: January 18, 2022Publication date: April 4, 2024Applicant: OBSIDIAN THERAPEUTICS, INC.Inventors: Kyle Pedro, James Alexander Storer, Jan ter Meulen, Rachel Burga, Mithun Khattar, Michelle Ols, Jeremy Tchaicha, Shyamsundar Subramanian
-
Publication number: 20240075064Abstract: The present disclosure provides compositions and methods for expanding T cells or tumor infiltrating lymphocytes (TILs) in vitro. K562 feeder cells engineered to express a costimulatory molecule (e.g., 41BB ligand (41BBL)) and either interleukin 21 (IL21) or interleukin 7 (IL7) can be used in a rapid expansion protocol (REP) step to expand the T cells or TILs. Thus, provided herein is a culture comprising T-cells or TILs and modified K562 feeder cells. The T cells can be modified to express a chimeric antigen receptor (CAR) or a T cell receptor (TCR) or the TILs can be modified to express membrane-bound IL15 (mbIL15). The T cells or TILs can be expanded in vitro using aREP without the use of exogenous interleukin 2 (IL2), and the expanded cells can be used in adoptive cell therapy for treatment of cancer without concomitant use of an exogenous cytokine such as IL2.Type: ApplicationFiled: January 18, 2022Publication date: March 7, 2024Applicant: OBSIDIAN THERAPEUTICS, INC.Inventors: Kutlu Goksu Elpek, Celeste Richardson, Michelle Lois Fleury, James Alex Storer, Shyamsundar Subramanian, Mithun Khattar
-
Publication number: 20220332780Abstract: The present disclosure provides drug responsive domains derived from human carbonic anhydrase 2 that can modulate protein stability for human interleukin 15 (EL15) payloads, as well as compositions and methods of use thereof.Type: ApplicationFiled: September 10, 2020Publication date: October 20, 2022Inventors: Kutlu Goksu ELPEK, Dhruv Kam SETHI, Meghan C. LANGLEY, Tucker Read EZELL, Dexue SUN, Jennifer Leah GORI, Geetha Hanna MYLVAGANAM, Michelle OLS, Michelle FLEURY, Celeste RICHARDSON, James A. STORER, Vipin SURI, Shyamsundar SUBRAMANIAN, Colleen FOLEY, Molly Reed PERKINS, Jeremy Hatem TCHAICHA, Scott Francis HELLER
-
Publication number: 20220133801Abstract: Provided herein are tumor-infiltrating lymphocytes (TILs) engineered to express a membrane-bound interleukin 15 (mbIL15). The mbIL15 TILs can be expanded in vitro using a rapid expansion protocol without the use of exogenous interleukin 2 (IL2) and can be used in adoptive cell therapy without concomitant use of an exogenous cytokine such as IL2. The TIL can be further engineered such that the mbIL15 is operably linked to one or more drug responsive domains (DRDs), polypeptides that can regulate the abundance and/or activity of the IL15 upon binding of the DRD with a ligand. Also provided herein are components for making the modified TILs and methods for making and using the modified TILs.Type: ApplicationFiled: January 18, 2022Publication date: May 5, 2022Inventors: Mithun Khattar, Shyamsundar Subramanian, Rachel Burga, Michelle Lynn Ols, Jan ter Meulen, Kyle Pedro, Jeremy Hatem Tchaicha
-
Patent number: 11058725Abstract: The present disclosure provides drug responsive domains derived from human carbonic anhydrase 2 that can modulate protein stability for human interleukin 15 (IL15) payloads, as well as compositions and methods of use thereof.Type: GrantFiled: September 10, 2020Date of Patent: July 13, 2021Assignee: Obsidian Therapeutics, Inc.Inventors: Kutlu Goksu Elpek, Dhruv Kam Sethi, Meghan C. Langley, Tucker Read Ezell, Dexue Sun, Jennifer Leah Gori, Geetha Hanna Mylvaganam, Michelle Ols, Michelle Fleury, Celeste Richardson, James A. Storer, Vipin Suri, Shyamsundar Subramanian, Colleen Foley, Molly Reed Perkins, Jeremy Hatem Tchaicha, Scott Francis Heller
-
Publication number: 20210069248Abstract: The present disclosure provides drug responsive domains derived from human carbonic anhydrase 2 that can modulate protein stability for human interleukin 15 (IL15) payloads, as well as compositions and methods of use thereof.Type: ApplicationFiled: September 10, 2020Publication date: March 11, 2021Applicant: Obsidian Therapeutics, Inc.Inventors: Kutlu Goksu ELPEK, Meghan C. LANGLEY, Tucker Read EZELL, Dexue SUN, Jennifer Leah GORI, Geetha Hanna MYLVAGANAM, Michelle OLS, Michelle FLEURY, Celeste RICHARDSON, James A. STORER, Vipin SURI, Shyamsundar SUBRAMANIAN, Colleen FOLEY, Molly Reed PERKINS, Jeremy Hatem TCHAICHA, Scott Francis HELLER
-
Patent number: 9611455Abstract: The present invention relates to the use of increased culture pH, relative to standard insect cell culture conditions, during baculovirus infection of lepidopteran insect cells to enable production of recombinant chikungunya (CHIKV) virus like particles (VLPs). The invention further relates to adapted insect cell lines derived from insect cells such as Sf21, which can grow robustly at elevated culture pH, the use of said cell lines to recombinantly produce pH sensitive proteins in the correct conformation and increase expression of recombinant proteins relative to standard insect cell lines. In some embodiments of the invention, the cells are useful for recombinant production of CHIKV VLPs. The invention also relates to a method for the production of a pH-adapted lepidopteran insect cell line. In some embodiments of said method, the cell line is produced and/or maintained in reduced phosphate serum-free insect cell media.Type: GrantFiled: March 13, 2014Date of Patent: April 4, 2017Assignee: Merck Sharp & Dohme Corp.Inventors: James M. Wagner, Shyamsundar Subramanian, David Pajerowski
-
Publication number: 20160040124Abstract: The present invention relates to the use of increased culture pH, relative to standard insect cell culture conditions, during baculovirus infection of lepidopteran insect cells to enable production of recombinant chikungunya (CHIKV) virus like particles (VLPs). The invention further relates to adapted insect cell lines derived from insect cells such as Sf21, which can grow robustly at elevated culture pH, the use of said cell lines to recombinantly produce pH sensitive proteins in the correct conformation and increase expression of recombinant proteins relative to standard insect cell lines. In some embodiments of the invention, the cells are useful for recombinant production of CHIKV VLPs. The invention also relates to a method for the production of a pH-adapted lepidopteran insect cell line. In some embodiments of said method, the cell line is produced and/or maintained in reduced phosphate serum-free insect cell media.Type: ApplicationFiled: March 13, 2014Publication date: February 11, 2016Applicant: Merck Sharp & Dohme Corp.Inventors: James M. Wagner, Shyamsundar Subramanian, David Pajerowski, Danilo Casimiro, John Balliet (DECEASED), Jessica Flynn, Jennifer Galli, Patrick McHugh, Dawn Hall, Christopher Daniels, Jennifer Girard
-
Publication number: 20150044250Abstract: The present invention relates to recombinant C. difficile toxin A (TcdA) and toxin B (TcdB) and binary toxin A (CDTa) proteins comprising specifically defined mutations relative to the native toxin sequence that substantially reduce or eliminate toxicity. The invention also relates to vaccines and immunogenic compositions comprising these recombinant toxins, as well as combinations of these toxins with binary toxin B (CDTb), which are capable of providing protection against C. difficile infection and/or the effects thereof. The invention also relates to methods of inducing an immune response to C. difficile comprising administering the vaccines and immunogenic compositions described herein to a patient. The invention also encompasses methods of expressing recombinant C. difficile toxin A and toxin B and CDTa mutants and CDTb in recombinant expression systems.Type: ApplicationFiled: January 25, 2013Publication date: February 12, 2015Applicants: Intervet Inc., Merck Sharp & Dohme Corp.Inventors: Jon Henry Heinrichs, Jean-Luc Bodmer, Susan Lynn Secore, Aaron Rudy Goerke, Ivette Caro-Aguilar, Marie-Pierre Gentile, Melanie S. Horton, Matthew Ryan Miezeiewski, Julie M. Skinner, Paulus Jacobus Antonius Sondermeijer, Shyamsundar Subramanian, Karin Huberdina Antonia van der Heijden-Liefkens, Su Wang, Jinfu Xie, Rachel Flora Xoconostle, Julie K. Zorman